Education
About Us
Working with TipRanks
Follow Us
Synaptogenix, Inc. (SNPX)
:SNPX
SNPX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.84 - $5.38
Previous CloseN/A
Volume20.55K
Average Volume (3M)10.53K
Market Cap
$2.98M
Enterprise ValueN/A
Total Cash (Recent Filing)$17.38M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.86
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-10.34
Shares Outstanding1,389,815
10 Day Avg. Volume18,426
30 Day Avg. Volume10,532
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
Synaptogenix News
PremiumCompany Announcements
Synaptogenix Restructures Leadership Amid Strategic Refocus
PremiumCompany Announcements
Synaptogenix CEO Dr. Tuchman’s Tenure Extended Through 2024---
Ownership Overview
9.39%
Insiders
1.00% Mutual Funds
<0.01% Other Institutional Investors
89.41% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
SNPX FAQ
What was Synaptogenix, Inc.’s price range in the past 12 months?
Synaptogenix, Inc. lowest stock price was $1.84 and its highest was $5.38 in the past 12 months.
What is Synaptogenix, Inc.’s market cap?
Synaptogenix, Inc.’s market cap is $2.98M.
When is Synaptogenix, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Synaptogenix, Inc.’s earnings last quarter?
Currently, no data Available
Is Synaptogenix, Inc. overvalued?
According to Wall Street analysts Synaptogenix, Inc.’s price is currently Overvalued.
Does Synaptogenix, Inc. pay dividends?
Synaptogenix, Inc. does not currently pay dividends.
What is Synaptogenix, Inc.’s EPS estimate?
Synaptogenix, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Synaptogenix, Inc. have?
Synaptogenix, Inc. has 1,389,815 shares outstanding.
What happened to Synaptogenix, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Synaptogenix, Inc.?
Currently, no hedge funds are holding shares in SNPX
---
Company Description
Synaptogenix, Inc.
Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York.
---
SNPX Stock 12 Month Forecast
Average Price Target
―Technical Analysis
ACADIA Pharmaceuticals
―
Biogen
―
Corcept Therapeutics
―
Axsome Therapeutics
―
Annovis Bio
―
Best Analysts Covering SNPX
1 Year
1 Year Success Rate
0/1 ratings generated profit
1 Year Average Return
-47.70%
upgraded a buy rating 9 months ago
Copying Jason McCarthy's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -47.70% per trade.
---